2024-03-21 00:45:11
2024-03-21 08:45 Economic Daily reporter Xie Baihong/Real-time reporting
Shenghua Science and Technology (6492) announced on the 20th that the company has developed Silmitasertib (CX-4945), a new drug for the treatment of community-type pneumonia caused by infection with the new coronavirus or influenza virus. The first patient was successfully admitted in the second phase clinical trial at National Taiwan University Hospital on the 20th. Since the epidemic is still at a plateau It is expected that the closing process will be accelerated.
Biotech stated that Silmitasertib’s innovative drug mechanism targets human host cells, is less affected by virus mutations, and can inhibit the excessive expression of immune factors, preventing patients from turning into severe disease and accelerating their recovery to health. At the same time, compared with Silmitasertib (CX-4945), the next-generation drug CX-8184 is more highly active and has better neutralization and inhibition capabilities once morest viruses. It is currently moving towards the development of new dosage forms that can directly act on the lungs, such as If all goes well, it will have the opportunity to become a novel drug that is easy to use and has the potential to fight broad-spectrum viruses.
Biotech pointed out that Silmitasertib (CX-4945) acts directly on the mechanism of human host cells and has the therapeutic potential to reduce pneumonia or concurrent immune diseases caused by infection with pathogens by regulating the CK2 protein kinase of inflammatory responses of immune factors. The trial was conducted in five large hospitals in northern Taiwan. It includes National Taiwan University Hospital, National Taiwan University Cancer Center Branch, Yadong Hospital, Military General Hospital, and Taoyuan Hospital of the Ministry of Health and Welfare, and all have chief physicians as project hosts.
According to statistics, the number of secondary diagnoses of COVID-19, influenza and other respiratory diseases has increased significantly recently. In addition to immunity debt, the world also faces the challenge of immunity theft. An article in the American Medical Journal this year pointed out that following infection with the new coronavirus, the body’s T cells are damaged, causing the immune system’s ability to protect once morest viruses and bacteria to weaken. It is as if the immune function has been stolen by the new coronavirus, and the effects can last for a long time. up to one year. WHO Secretary-General Tedros Adhanom Ghebreyesus recently pointed out that it is only a matter of time, not probability, that another wave of Disease X pandemic may break out globally.
Biotech stated that it hopes that this Phase II human trial of community-type pneumonia can use Silmitasertib (CX-4945) to intervene early in the course of the patient’s disease. In addition to inhibiting viral replication, it also reduces the excessive expression of immune factors and blocks the occurrence of pneumonia and even other immune diseases. risks and accelerate patients’ recovery to health. If there are positive results, an effective drug network will be built for the next wave of global epidemic prevention.
COVID-19 Health Huake Rehabilitation
recommended article
1711065768
#Silmitasertib #communitytype #pneumonia #drug #Shenghuake #received #patient #phase #clinical #trials #Market #Focus #Securities
